Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2007

View Archived Issues

New data provided by EAE models for multiple sclerosis

New clinical trial results for rotigotine in Parkinson's disease, restless legs syndrome

Antitumor activity of novel PI3K inhibitor reported by Zentaris

Novel CDK inhibitor SCH-727965 shows broad antitumor activity in preclinical studies

New therapeutic agents for benign prostatic hyperplasia disclosed in recent Ranbaxy patent

Recent data suggest that lacosamide has low potential for drug-drug interaction

Novel antiinfective agents disclosed in recent patent literature

Novel agents for cardiovascular disorders disclosed in recent Taisho and Boehringer patents

Biosite and Beckman Coulter amend merger agreement

Phase Ib study to begin for optimized TPM-02/Insulin

Cardiome Pharma in-licenses GED-aPC

Rituximab beneficial in myositis, polyneuropathy, neuromyelitis optica

Laquinimod reduces disease activity in relapsing-remitting MS

Phase III trial finds Imagify non-inferior to nuclear stress

Positive phase I findings for DG-051 for prevention of heart attack

Schering-Plough reviews Q1

TH-302 demonstrates activity in orthotopic models of cancer

Pro-Pharmaceuticals and Digna collaborate in hepatitis C

ViroPharma to establish European subsidiary for maribavir

Ark seeks clearance for phase III study of Trinam

ThromboGenics reviews preclinical pipelines progression

Target enrollment reached in phase IIb study of ozarelix for BPH

Cadence plans to increase patient numbers in phase III Omnigard trial

Enrollment under way in phase II study of FTY-720 for relapsing-remitting MS

Belinostat studied with doxorubicin in new phase I/II trial for soft tissue sarcomas

Enzon cleared to begin phase I study of PEG-SN38 in cancer

Tbeta4 cleared for phase II study in diabetics undergoing vitrectomy surgery

Herceptin approved for new breast cancer indication in E.U.

Supprelin-LA approved for central precocious puberty

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...